You are here: Industry Insights > Merck

News List

Merck's Keytruda hits the skids in pivotal trial, putting its liver cancer nod at risk fiercepharma
February 21, 2019
Merck & Co.’s immunotherapy Keytruda has been hitting its trial targets so often, it’s tempting to think it can't miss. But it can—and Tuesday’s data in liver cancer proves it.
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early fiercepharma
February 20, 2019
The race is on between two Big Pharmas to snag a new indication in kidney cancer, but thanks to new data from Merck & Co., it may not matter who gets there first.
Merck Group and Pfizer announce positive results for combo therapy for RCC pharmaceutical-technology
February 19, 2019
Pfizer and German-based Merck Group have published promising interim results from their Phase III JAVELIN Renal 101 trial evaluating the efficacy and safety of ....
Merck initiates three Phase III trials into Keytruda for prostate cancer pharmaceutical-technology
February 18, 2019
As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck has announced three new Phase III trials into the safety and efficacy of Keytruda (pembrolizumab) for patients with metastatic castration-resistant prostate cancer....
Merck/Pfizer up the pressure on BMS in first-line kidney cancer pharmaphorum
February 14, 2019
The FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney cancer, setting up a possible approval in June and piling more pressure on Bristol-Myers Squibb.
USFDA accepts Merck and Pfizer’s sBLA for Renal Cancer drug biospectrumasia
February 13, 2019
The clinical development program for avelumab, known as JAVELIN, involves at least 30 clinical programs and more than 9,000 patients evaluated across more than 15 different tumor types.
FDA agrees to review Merck and Pfizer’s sBLA for Bavencio and Inlyta pharmaceutical-technology
February 13, 2019
The US Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) submitted by Merck subsidiary EMD Serono and Pfizer for a Bavencio (avelumab) and Inlyta (axitinib) combination to .....
Merck Granted U.S. Patent for novel combination of Artificial Intelligence and Blockchain Technology worldpharmanews
January 31, 2019
Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO).
Merck and Tencent announce collaboration on intelligent digital healthcare services in China worldpharmanews
January 28, 2019
Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services.
Merck enters into an exclusive licensing agreement with Vertex biospectrumasia
January 28, 2019
Merck, a leading science and technology company has announced that it has entered into an exclusive licensing agreement with Vertex Pharmaceuticals Incorporated

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page